Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells

Triple negative breast cancer (TNBC) is an aggressive form of breast cancer which accounts for 15–20% of this disease and is currently treated with genotoxic chemotherapy. The BCL2 (B-cell lymphoma 2) family of proteins controls the process of mitochondrial outer membrane permeabilization (MOMP), wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucantoni, Federico, Lindner, Andreas U., O’Donovan, Norma, Düssmann, Heiko, Prehn, Jochen H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833806/
https://www.ncbi.nlm.nih.gov/pubmed/29352235
http://dx.doi.org/10.1038/s41419-017-0039-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833806/
https://www.ncbi.nlm.nih.gov/pubmed/29352235
http://dx.doi.org/10.1038/s41419-017-0039-y

Ejemplares similares